Arcellx Inc (ACLX) Stock Forecast & Price Target

Compare

261 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ACLX Analyst Ratings

Strong Buy

14 Buy

2 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Arcellx

Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ACLX Stock 12 Month Forecast

Average Price Target

$115.00

▲(53.42% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Arcellx Inc in the last 3 months. The average price target is $115.00 with a high forecast of $134.00 and a low forecast of $88.00. The average price target represents a 53.42% change from the last price of $74.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","78":"$78","97":"$97","116":"$116","135":"$135"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$134.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$88.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,78,97,116,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.25,93.61538461538461,96.98076923076923,100.34615384615384,103.71153846153847,107.07692307692308,110.4423076923077,113.8076923076923,117.17307692307692,120.53846153846155,123.90384615384616,127.26923076923077,130.6346153846154,{"y":134,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.25,92.15384615384616,94.0576923076923,95.96153846153847,97.86538461538461,99.76923076923077,101.67307692307692,103.57692307692308,105.48076923076923,107.38461538461539,109.28846153846153,111.1923076923077,113.09615384615384,{"y":115,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.25,90.07692307692308,89.90384615384616,89.73076923076923,89.5576923076923,89.38461538461539,89.21153846153847,89.03846153846153,88.86538461538461,88.6923076923077,88.51923076923077,88.34615384615384,88.17307692307692,{"y":88,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.69,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.14,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$134.00

Average Price Target$115.00

Lowest Price Target$88.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Willey

Stifel Nicolaus

$129→$127

Buy

69.42%

Upside

Reiterated

11/25/25

Stifel Nicolaus Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Biren Amin

Piper Sandler

$115

Buy

53.42%

Upside

Reiterated

11/25/25

Arcellx Inc (ACLX) Receives a Buy from Piper Sandler

John Newman

Canaccord Genuity

$130

Buy

73.43%

Upside

Reiterated

11/25/25

Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity

Michael Schmidt

Guggenheim

$120

Buy

60.09%

Upside

Reiterated

11/24/25

Arcellx weakness on competitive worries 'overdone,' says GuggenheimArcellx weakness on competitive worries 'overdone,' says Guggenheim

Jason Gerberry

Bank of America Securities

$112

Buy

49.41%

Upside

Reiterated

11/24/25

Promising Outlook for Arcellx Inc's Anito-cel Therapy in Multiple Myeloma Treatment

Geoff Meacham

Citi

$110

Buy

46.74%

Upside

Reiterated

11/24/25

Citi says Arcellx weakness on 'highly preliminary' Kelonia data an overreactionCiti says Arcellx weakness on 'highly preliminary' Kelonia data an overreaction

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Arcellx initiated with a Peer Perform at Wolfe ResearchArcellx initiated with a Peer Perform at Wolfe Research

Gil Blum

Needham

$105

Buy

40.07%

Upside

Reiterated

11/07/25

Arcellx's Promising Clinical Data and Strong Financial Position Justify Buy Rating with $105 Target Price

Cory Kasimov

Evercore ISI

$115

Buy

53.42%

Upside

Reiterated

11/06/25

Evercore ISI Keeps Their Buy Rating on Arcellx Inc (ACLX)

Emily Bodnar

H.C. Wainwright

$115

Buy

53.42%

Upside

Reiterated

11/06/25

Promising Developments and Strategic Plans Boost Confidence in Arcellx Inc.'s Anito-celValuation and Risks. Our Buy rating and $115 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2037 and assign a 11% discount rate and 2% terminal value, which is in line with other companies in our coverage with platform technologies. We currently assume value for anito-cel for treatment of 5L MM with a 80% POS and 2L-4L MM with a 70% POS, and for ACLX-002 for AML with 30% POS, and have not included other pipeline assets or indications in our valuation.

Asthika Goonewardene

Truist Financial

$134

Buy

78.76%

Upside

Reiterated

11/06/25

Truist Financial Sticks to Their Buy Rating for Arcellx Inc (ACLX)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/05/25

Arcellx Inc's Promising Developments and Strategic Partnerships Drive Buy Rating11:31 PM Arcellx (NASDAQ: ACLX) Buy (1) ESG Target: NA Q3 EPS: The BLA Report THE TD COWEN INSIGHT Anito-cel’s BLA filing is imminent, with a launch expected mid-to-late '26, and we believe it will be rapid given its clinical profile and Kite partnership. The ASH data is largely derisked and no delayed neurotox/colitis has emerged as of the ASH abstract. There is a 50/50 chance of 24-month PFS at ASH and the data cut could be used for the label, but this has not been confirmed. Reiterate Buy. Or Colitis... Recall, Arcellx will report updated Phase I iMMagine-1 data at 2025 (Saturday, December 6, 2025).

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/03/25

Arcellx's Anito-cel Shows Promising Phase II Results and Market Potential, Earning Buy Rating

Peter Lawson

Barclays

$115

Buy

53.42%

Upside

Reiterated

10/31/25

Arcellx Inc (ACLX) Gets a Buy from Barclays

Daina Graybosch

Leerink Partners

$104→$109

Buy

45.41%

Upside

Reiterated

10/20/25

Leerink Partners Keeps Their Buy Rating on Arcellx Inc (ACLX)We are increasing our ACLX PT to $109 from $104 after refining our COGS contribution; reiterate OP rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Willey

Stifel Nicolaus

$129→$127

Buy

69.42%

Upside

Reiterated

11/25/25

Stifel Nicolaus Sticks to Its Buy Rating for Arcellx Inc (ACLX)

Biren Amin

Piper Sandler

$115

Buy

53.42%

Upside

Reiterated

11/25/25

Arcellx Inc (ACLX) Receives a Buy from Piper Sandler

John Newman

Canaccord Genuity

$130

Buy

73.43%

Upside

Reiterated

11/25/25

Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity

Michael Schmidt

Guggenheim

$120

Buy

60.09%

Upside

Reiterated

11/24/25

Arcellx weakness on competitive worries 'overdone,' says GuggenheimArcellx weakness on competitive worries 'overdone,' says Guggenheim

Jason Gerberry

Bank of America Securities

$112

Buy

49.41%

Upside

Reiterated

11/24/25

Promising Outlook for Arcellx Inc's Anito-cel Therapy in Multiple Myeloma Treatment

Geoff Meacham

Citi

$110

Buy

46.74%

Upside

Reiterated

11/24/25

Citi says Arcellx weakness on 'highly preliminary' Kelonia data an overreactionCiti says Arcellx weakness on 'highly preliminary' Kelonia data an overreaction

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Arcellx initiated with a Peer Perform at Wolfe ResearchArcellx initiated with a Peer Perform at Wolfe Research

Gil Blum

Needham

$105

Buy

40.07%

Upside

Reiterated

11/07/25

Arcellx's Promising Clinical Data and Strong Financial Position Justify Buy Rating with $105 Target Price

Cory Kasimov

Evercore ISI

$115

Buy

53.42%

Upside

Reiterated

11/06/25

Evercore ISI Keeps Their Buy Rating on Arcellx Inc (ACLX)

Emily Bodnar

H.C. Wainwright

$115

Buy

53.42%

Upside

Reiterated

11/06/25

Asthika Goonewardene

Truist Financial

$134

Buy

78.76%

Upside

Reiterated

11/06/25

Truist Financial Sticks to Their Buy Rating for Arcellx Inc (ACLX)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/05/25

Sami Corwin

William Blair

―

Buy

―

Reiterated

11/03/25

Arcellx's Anito-cel Shows Promising Phase II Results and Market Potential, Earning Buy Rating

Peter Lawson

Barclays

$115

Buy

53.42%

Upside

Reiterated

10/31/25

Arcellx Inc (ACLX) Gets a Buy from Barclays

Daina Graybosch

Leerink Partners

$104→$109

Buy

45.41%

Upside

Reiterated

10/20/25

Leerink Partners Keeps Their Buy Rating on Arcellx Inc (ACLX)We are increasing our ACLX PT to $109 from $104 after refining our COGS contribution; reiterate OP rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcellx Inc

1 Month

xxx

Success Rate

10/12 ratings generated profit

Average Return

+10.09%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 83.33% of your transactions generating a profit, with an average return of +10.09% per trade.

3 Months

xxx

Success Rate

9/12 ratings generated profit

Average Return

+17.58%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +17.58% per trade.

1 Year

Jason GerberryBank of America Securities

Success Rate

20/21 ratings generated profit

Average Return

+43.73%

reiterated a buy rating 2 days ago

Copying Jason Gerberry's trades and holding each position for 1 Year would result in 95.24% of your transactions generating a profit, with an average return of +43.73% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+69.57%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +69.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACLX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ACLX has received 25 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ACLX average Analyst price target in the past 3 months is 115.00.

Each month's total comprises the sum of three months' worth of ratings.

ACLX Financial Forecast

ACLX Earnings Forecast

Next quarter’s earnings estimate for ACLX is -$1.02 with a range of -$1.22 to -$0.67. The previous quarter’s EPS was -$0.99. ACLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ACLX has Performed in-line its overall industry.

ACLX Sales Forecast

Next quarter’s sales forecast for ACLX is $12.49M with a range of $0.00 to $54.90M. The previous quarter’s sales results were $4.95M. ACLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ACLX has Performed in-line its overall industry.

ACLX Stock Forecast FAQ

What is ACLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcellx Inc’s 12-month average price target is 115.00.

What is ACLX’s upside potential, based on the analysts’ average price target?

Arcellx Inc has 53.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ACLX a Buy, Sell or Hold?

Arcellx Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.

What is Arcellx Inc’s price target?

The average price target for Arcellx Inc is 115.00. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $134.00 ,the lowest forecast is $88.00. The average price target represents 53.42% Increase from the current price of $74.96.

What do analysts say about Arcellx Inc?

Arcellx Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of ACLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Arcellx Inc (ACLX) Stock Forecast & Price Target

ACLX Analyst Ratings

ACLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcellx Inc

ACLX Analyst Recommendation Trends

ACLX Financial Forecast

ACLX Earnings Forecast

ACLX Sales Forecast

ACLX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts